Genes that when inactivated result in cell death or enhanced cell growth, respectively are defined as lethal and rescuer genes. The ability to identify these genes in large-scale automated screening campaigns could lead to the discovery of valuable new drug targets.
A genome-wide lethality screen that relies on RNA interference technology and led to the validation of 239 gene candidates essential for cell survival is described in ASSAY and Drug Development Technologies, a peer-reviewed journal published from Mary Ann Liebert, Inc., publishers. The article is available free on the ASSAY and Drug Development Technologies website.
Epigenetics
In the recent years 'epigenetics' represents inheritable changes in gene expression that do not include DNA alterations.
Advertisement
A team of researchers led by Bhavneet Bhinder and Hakim Djaballah, Memorial Sloan-Kettering Cancer Center, New York, NY, present their work in the article "An Arrayed Genome-Scale Lentiviral-Enabled Short Hairpin RNA Screen Identifies Lethal and Rescuer Gene Candidates."
The authors developed a high-stringency analysis method used to determine which genes result in cell death when they are "knocked down." Gene knockdown is achieved via an RNA interference approach, using double-stranded RNA molecules called short hairpin RNAs, or shRNAs. A shRNA binds to a target gene, blocking gene expression. The high-throughput screen is carried out in cells in 384-well microtiter plates.
Source: Eurekalert
Source: Eurekalert
US Supreme Court to Rule on the Most High Profile Genetics Case in History
The US Supreme Court judges are currently hearing the most high profile genetics case in history.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Genetics & Stem Cells News
NGN-401 is a first ever new gene therapy discovered to cure a rare genetic brain disorder called Rett Syndrome.
Among MS patients, the stem cells showed a neuroprotective role, guarding nerve cells from further decline.
New possibilities for research on digestive diseases have been set by complete decoding of the Y chromosome.
UK has given the green light to the world's inaugural gene therapy for sickle-cell disease and thalassemia.
1 in 25 people had a genotype linked to short lifetime, which includes BRCA2 and LDLR genes, that reduced lifespan by seven years, and six years respectively.